000			02564na a2200265 4500
003			PC5878
005			20210706062654.0
008			130622s2011 xxx||||| |||| 00| 0 eng d
010			_a
024			_a
040			_cH12O
041			_aeng
100			_91250 _aDelgado Jiménez, Juan Francisco _eCardiología
245	0	0	_aImprovement in chronic renal failure after mycophenolate mofetil introduction and cyclosporine dose reduction: four-year results from a cohort of heart transplant recipients _h[artículo]
260			_bTransplantation Proceedings, _c2011.
300			_a43(7):2699-2706.
337			_a
500			_aFormato Vancouver: Manito N, Rábago G, Palomo J, Arizón JM, Delgado J, Almenar L, et al. Improvement in chronic renal failure after mycophenolate mofetil introduction and cyclosporine dose reduction: four-year results from a cohort of heart transplant recipients. Transplant Proc. 2011;43(7):2699-706.
501			_aPMID: 21911149
504			_aContiene 23 referencias.
520			_aChronic renal failure (CRF) due to calcineurin inhibitor (CNI) nephrotoxicity is a frequent complication among heart transplant (HT) recipients. Small studies have suggested that the introduction of mycophenolate mofetil (MMF) can help to reduce CM doses thereby to maintaining or improving renal function. We conducted a 4-year, prospective, multicenter study in 89 maintenance HT recipients at 5.6 +/- 2.7 years postgrafting who displayed CRF (serum creatinine > 1.4 mg/dL) and were undergoing treatment with cyclosporine and prednisone +/- azathioprine. We introduced MMF and reduced cyclosporine to level below 100 ng/mL. Creatinine clearance (CrCl), acute rejection episodes, and survival were through retrospectively compared with a contemporary cohort of HT recipients who were not treated with MMF (control group; n = 38). After conversion to MMF, a rapid increase was observed in the CrCI, which was maintained over the follow-up: namely, CrCl at month 6 and at 4 years were 51.0 +/- 15.6 and 54.1 +/- 15.6 mL/min versus 41.9 +/- 11.1 mL/min at baseline (P < .0001). No renal function changes were observed among the control group. Acute rejection rates were 5.6% and 2.6% in the MMF versus control groups (P = NS) with 4-year survivals >85%. In conclusion, the introduction of MMF allowed a safe reduction of cyclosporine and significantly improved renal function after 4 years.
710			_9119 _aServicio de Cardiología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc5878.pdf _ySolicitar documento
942			_2ddc _cART _n0
999			_c5878 _d5878